Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4808962 | 0.98 | ALOX15 (0.32) | ALOX15L3MBTL1HRH3 | |
| SCHEMBL4922025 | 0.71 | ALOX15 (0.32) | ALOX15 | |
| SCHEMBL4462970 | 0.70 | HRH3 (0.44) | L3MBTL1CYP1A2CYP3A4SIGMAR1HRH3 | |
| SCHEMBL2069442 | 0.62 | — | — | |
| SCHEMBL15777461 | 0.61 | HRH3 (0.44) | L3MBTL1CYP1A2SIGMAR1ALDH1A1TSHR | |
| SCHEMBL6230793 | 0.58 | ACHE (0.40) | ALOX15SIGMAR1ALDH1A1HRH3HTT | |
| SCHEMBL23828671 | 0.55 | HRH3 (0.69) | L3MBTL1CYP1A2SIGMAR1ALDH1A1TSHR | |
| SCHEMBL12826 | 0.55 | HRH3 (0.69) | L3MBTL1CYP1A2SIGMAR1ALDH1A1TSHR | |
| SCHEMBL5466977 | 0.55 | HRH3 (0.69) | L3MBTL1CYP1A2SIGMAR1ALDH1A1TSHR | |
| SCHEMBL134912 | 0.55 | HRH3 (0.69) | L3MBTL1CYP1A2SIGMAR1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531547-B2 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20070049758-A1 | Urogenital disorders; incotinence; analgesics; respiratory system disorders; gastrointestinal disorders; premenstrual tension | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049758-A1 | Urogenital disorders; incotinence; analgesics; respiratory system disorders; gastrointestinal disorders; premenstrual tension | P2RX3, P2RX1, P2RX2 | ALOX15 2806/4885L3MBTL1 3850/4885CYP1A2 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.